Head-to-head evidence
Elranatamab vs REGN5459
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
Elranatamab
Marketed by Pfizer
NCT05014412 · Phase 2 · completed
The study was nonrandomized, open-label, and single-arm, with all 85 treated participants receiving elranatamab and no placebo or active comparator. Its primary endpoint was a clinical safety outcome—grade 2 or higher cytokine release syndrome—and was reported in 12 participants, but the uncontrolled design provides limited evidence of treatment effectiveness.
Next expected readout: December 2026 · NCT06421675 (registry estimate)
REGN5459
Developed by Regeneron Pharmaceuticals
NCT04083534 · Phase 1/2 · completed
This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elranatamab's landscape · REGN5459's landscape